International investors find Chinese secondary PE market an alternative amid U.S.-China tensions; QuantumPharm is the first IPO under Hong Kong's new measure for pre-revenue specialist technology firms; and China releases new carbon measuring standards foreseeing new EU carbon tariffs.
Shanghai FTZ elaborates on the general data of the public fund sector
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
Successful U.S. IPO of Chinese EV brand suggests rising investor confidence, but regulatory risks still loom; Burberry wins trademark infringement and unfair competition lawsuit; and China proposes guidelines to it's lithium battery sector amid overcapacity concerns.
CSRC intensifies IPO random inspection
Surveillance camera maker Zhejiang Dahua exits U.S. market amid sanctions; China implements measures to boost mainland companies seeking to list in Hong Kong; and China rolls out measures to boost overseas investments in domestic sci-tech companies.
Shenzhen expands the scope of PE investments
